Abstract
Gemcitabine monophosphate (dFdCMP), one of the intracellular forms of phosphorylated gemcitabine, determines its antitumor activity. A pharmaco-molecular model for determining gemcitabine relative monophosphate levels has been developed based on the assessment of the activity of ENT1, ENT2 channels and dCK, CDA enzymes in tumor tissue. Gemcitabine relative monophosphate levels is a more relevant predictive factor of gemcitabine resistance of bladder cancer when compared with the expression of individual markers related to dFdCMP formation.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
